SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data for deramiocel, including a reported slowing of upper-limb decline after placebo patients switched to treatment, is driving attention around its World Muscle Society presentation. Many traders view the results as supportive of the Duchenne muscular dystrophy therapy and the pending FDA review, while others question whether open-label findings resolve the agencys statistical-analysis concerns; short-squeeze talk is also prominent.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA administrative judges pause of the remaining cannabis rescheduling case, pending review of a government report on drug-scheduling procedures, has delayed a recommendation on broader Schedule III treatment. Traders debate whether the procedural delay threatens the catalyst and warrants further selling or is a temporary setback and buying opportunity; the earlier medical-marijuana rule was not reversed.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas positive Phase 3 Hetlioz results in delayed sleep-wake phase disorder, with the trial meeting its primary endpoint and an FDA submission planned, are driving attention. Traders largely welcome the potential label expansion and new commercial opportunity, while some caution that the study was small and debate how much the news may translate into lasting stock gains.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths SPAC merger and Nasdaq listing, tied to a large planned XRP treasury, are driving attention alongside sharp moves and trading halts. Traders see XRPN and its warrants as leveraged XRP exposure, while others question their valuation and flag merger, redemption, and dilution risks.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

JANA Partners call for Six Flags to explore a sale is driving discussion, with traders debating whether a sale could unlock value or distract management and add costs while the company tackles its debt and operating challenges. The bearish reaction also reflects concern over the stocks continued slide, while some holders argue the companys assets are undervalued.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphases IQ Solid State Transformer push into AI data-center power is drawing attention, with traders focused on U.S. production progress and planned demonstrations and customer pilots. Bulls see a potential growth catalyst and short-squeeze setup, while skeptics point to the long commercialization timeline, interest-rate sensitivity, and weak residential-solar demand.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebecs payroll and payments partnerships, particularly its Stellar-based enterprise payroll rollout and MoneyGram connectivity, are fueling discussion about real-world adoption and potential ZBCN utility. Bulls see growing usage as a long-term catalyst, while skeptics argue that partnerships have yet to translate into sustained token demand or price gains; Robinhood and BlackRock links remain speculation.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised 2026 revenue outlook, citing stronger demand for Amtagvi and Proleukin, drove a sharp rally and analyst target increases. Traders are debating whether short covering amplified the move, while also watching for upcoming lung-cancer trial data; a short squeeze remains speculation.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

Barclays cautious pre-Q3 outlook, citing limited earnings upside and emerging competition from Starlink, is feeding concern around T-Mobiles decline. Traders are split between viewing the selloff and fresh lows as an overreaction and expecting further weakness amid competitive and growth concerns.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Traders are positioning in UVIX as a leveraged volatility hedge, anticipating a VIX spike amid concerns about rates, oil, geopolitical risks and a potential market pullback. The debate centers on that speculative upside versus persistent losses from contango and daily decay, with many saying UVIX has failed to track market weakness as expected.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Principal Exchange-Traded Funds - Principal Equity Premium Income ETF

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$24.15
Prev Close	$24.24
Open	$24.18
Dividend Yield	N/A
50-Day Moving Average	$24.58
Beta	N/A
Avg. Volume	44,108.22
PE Ratio	N/A

52-Week High	$25.23
52-Week Low	$24.01
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

PCOV Fundamentals